Study of IL2-330 (rs2069762) gene polymorphism in Egyptian patients with lung cancer: a case-control study.

Abstract

Background: IL2 is one of the key cytokines essential for regulating the immune system and the inflammation-related carcinogenesis process. Few studies have examined the relationship between lung cancer and the IL2-330 (rs2069762) gene polymorphism, despite several studies demonstrating that it is linked to numerous cancer types.

Objective: Our study aimed to investigate the association between IL2-330 (rs2069762) polymorphism and lung cancer risk and explore the role of IL2-330 polymorphism in survival outcomes (OS and PFS).

Patients and methods: The study was conducted from October 2023 to November 2024, including 50 randomly selected patients diagnosed with lung cancer and 50 subjects matched for age and gender were used as controls in this case-control study. The IL2-330 (rs2069762) gene polymorphism was assessed using real-time PCR.

Results: We found that the AC genotype was associated with a notably lower risk of lung cancer in comparison to the AA genotype (95% CI: 0.06-0.61, p = 0.01). Conversely, the CC genotype showed no significant association with lung cancer risk when compared to the reference genotype. The comprehensive comparison of survival distributions among the AA, AC, and CC genotypes through the Log-Rank (Mantel-Cox) test indicated no statistically significant difference.

Conclusions: According to our research, The AC genotype of IL2-330 (rs2069762) is associated with a significantly higher survival rate and lower risk of lung cancer. Further future studies are needed to confirm these findings.